AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Tango Therapeutics CEO to Participate in 2025 Cantor Global Healthcare Conference
ByAinvest
Tuesday, Aug 26, 2025 7:04 am ET1min read
Tango Therapeutics announced that CEO Barbara Weber will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on September 3. The live webcast will be available on the company's website, and a replay will be archived for 90 days. Tango Therapeutics is a clinical-stage biotech company focused on discovering novel drug targets and delivering precision medicine for cancer treatment using synthetic lethality.
Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for cancer treatment, has announced that Barbara Weber, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Wednesday, September 3, from 2:45 to 3:15 PM ET. The live webcast will be available under the "Events & Presentations" tab on the "Investors" page of the company's website on the day of the event. A replay of the webcast will be archived on the company's website for 90 days following the presentation [1].The fireside chat will provide investors and healthcare professionals with an opportunity to hear directly from Dr. Weber about Tango Therapeutics' ongoing research, clinical trials, and strategic initiatives. The company's approach to precision oncology leverages the genetic principle of synthetic lethality to discover and develop therapies that target critical cancer pathways [2].
Tango Therapeutics has made significant progress in its clinical programs, including first patient dosing in two trials: a combination trial of TNG462 with Revolution Medicines' RAS(ON) inhibitors and a Phase 1/2 trial of TNG456 for glioblastoma. The company's collaboration with Gilead will conclude its research portion early, resulting in $53.8 million revenue recognition in Q3 2025 [3].
Investors can access the live webcast through the "Events & Presentations" section on the company's investor relations website. The presentation recording will remain available for 90 days following the event.
References:
[1] https://www.globenewswire.com/news-release/2025/08/26/3139116/0/en/Tango-Therapeutics-to-Participate-in-the-2025-Cantor-Global-Healthcare-Conference.html
[2] https://www.stocktitan.net/news/TNGX/tango-therapeutics-to-participate-in-the-2025-cantor-global-hmkg8bgwjj9p.html
[3] https://www.stocktitan.net/news/TNGX/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet